Skip to Main Content

WASHINGTON — PhRMA has a reputation in Washington for might, for money, for scorched-earth tactics, and for fighting even the tiniest of policy changes.

The pharmaceutical industry’s lobbying arm raised hell, for example, when lawmakers asked it to cover a slightly larger share of seniors’ drug costs. It spent years refusing to concede even minimal tweaks to an obscure bill related to generic competition.

advertisement

Over the last year, however, something changed. PhRMA, once a titanic lobbying powerhouse, lost its edge.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect

To submit a correction request, please visit our Contact Us page.